Literature DB >> 19819938

DRD2-related TaqIA polymorphism modulates motivation to smoke.

Yantao Zuo1, David G Gilbert, Norka E Rabinovich, Hege Riise, Rachel Needham, Jodi I Huggenvik.   

Abstract

INTRODUCTION: TaqIA polymorphism, a genetic variant associated with the expression level of dopamine D2 receptors in the brain, has been linked to various aspects of smoking behavior, including smoking prevalence, affective withdrawal symptoms, and smoking cessation outcome. However, its involvement in motivation to smoke cigarettes has not been elucidated.
METHODS: The present study examined the possible differences in self-reported reasons to smoke and craving for smoking in 160 smokers participating in a clinical trial.
RESULTS: Individuals with at least one A1 allele of the TaqIA polymorphism were more likely to report smoking for stimulating effects and to reduce negative affect compared with those lacking an A1 allele. The association of the A1 genotype with a higher probability and stronger motive to smoker to enhance cognitive functioning was evident in female but not in male smokers. Female A1 carriers also expected a greater likelihood of smoking for pleasure than those without an A1 allele. A1 subjects reported stronger craving for cigarettes during early days and the last phase of a 6-week abstinence period. DISCUSSION: These results support the idea that dopaminergic transmission plays an important role in the neurobiological basis of reasons for smoking and that the TaqIA variant is one of the genetic factors underlying individual differences in these aspects. These findings also have implications for improving treatment strategies to help individuals quit smoking by controlling their motivation to continue cigarette consumption.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19819938      PMCID: PMC2762931          DOI: 10.1093/ntr/ntp141

Source DB:  PubMed          Journal:  Nicotine Tob Res        ISSN: 1462-2203            Impact factor:   4.244


  60 in total

Review 1.  Drug addiction, dysregulation of reward, and allostasis.

Authors:  G F Koob; M Le Moal
Journal:  Neuropsychopharmacology       Date:  2001-02       Impact factor: 7.853

2.  Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism.

Authors:  E P Noble; K Blum; T Ritchie; A Montgomery; P J Sheridan
Journal:  Arch Gen Psychiatry       Date:  1991-07

3.  Selective dopamine antagonists reduce nicotine self-administration.

Authors:  W A Corrigall; K M Coen
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

4.  Effects of smoking on rapid information processing performance.

Authors:  K Wesnes; D M Warburton
Journal:  Neuropsychobiology       Date:  1983       Impact factor: 2.328

Review 5.  Theories of drug craving, ancient and modern.

Authors:  D C Drummond
Journal:  Addiction       Date:  2001-01       Impact factor: 6.526

Review 6.  The debate over dopamine's role in reward: the case for incentive salience.

Authors:  Kent C Berridge
Journal:  Psychopharmacology (Berl)       Date:  2006-10-27       Impact factor: 4.530

7.  Does the DRD2-Taq1 A polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome?

Authors:  Sean P David; Raymond Niaura; George D Papandonatos; William G Shadel; Gary J Burkholder; Dana M Britt; Amy Day; Jeffrey Stumpff; Kent Hutchison; Michael Murphy; Elaine Johnstone; Siân-Elin Griffiths; Robert T Walton
Journal:  Nicotine Tob Res       Date:  2003-12       Impact factor: 4.244

8.  The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire.

Authors:  T F Heatherton; L T Kozlowski; R C Frecker; K O Fagerström
Journal:  Br J Addict       Date:  1991-09

9.  Lack of association of DRD2 rs1800497 (Taq1A) polymorphism with smoking cessation in a nicotine replacement therapy randomized trial.

Authors:  Marcus R Munafò; Elaine C Johnstone; Michael F G Murphy; Paul Aveyard
Journal:  Nicotine Tob Res       Date:  2009-03-08       Impact factor: 4.244

10.  Dopamine and opioid gene variants are associated with increased smoking reward and reinforcement owing to negative mood.

Authors:  Kenneth A Perkins; Caryn Lerman; Amy Grottenthaler; Melinda M Ciccocioppo; Melissa Milanak; Cynthia A Conklin; Andrew W Bergen; Neal L Benowitz
Journal:  Behav Pharmacol       Date:  2008-09       Impact factor: 2.293

View more
  6 in total

1.  Beta-amyloid auto-antibodies are reduced in Alzheimer's disease.

Authors:  Bao-Xi Qu; Yunhua Gong; Carol Moore; Min Fu; Dwight C German; Ling-Yu Chang; Roger Rosenberg; Ramon Diaz-Arrastia
Journal:  J Neuroimmunol       Date:  2014-06-27       Impact factor: 3.478

2.  Cigarette experimentation in Mexican origin youth: psychosocial and genetic determinants.

Authors:  Anna V Wilkinson; Melissa L Bondy; Xifeng Wu; Jian Wang; Qiong Dong; Anthony M D'Amelio; Alexander V Prokhorov; Xia Pu; Robert K Yu; Carol J Etzel; Sanjay Shete; Margaret R Spitz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-10-25       Impact factor: 4.254

3.  Negative affect subtypes and craving differentially predict long-term cessation success among smokers achieving initial abstinence.

Authors:  Yantao Zuo; Norka E Rabinovich; David G Gilbert
Journal:  Psychopharmacology (Berl)       Date:  2016-12-27       Impact factor: 4.530

Review 4.  Obesity and the brain: how convincing is the addiction model?

Authors:  Hisham Ziauddeen; I Sadaf Farooqi; Paul C Fletcher
Journal:  Nat Rev Neurosci       Date:  2012-03-14       Impact factor: 34.870

5.  Is food addiction a valid and useful concept?

Authors:  H Ziauddeen; P C Fletcher
Journal:  Obes Rev       Date:  2012-10-12       Impact factor: 9.213

6.  The CHRNA3 rs578776 Variant is Associated with an Intrinsic Reward Sensitivity Deficit in Smokers.

Authors:  Jason D Robinson; Francesco Versace; Cho Y Lam; Jennifer A Minnix; Jeffrey M Engelmann; Yong Cui; Maher Karam-Hage; Sanjay S Shete; Gail E Tomlinson; Tina T-L Chen; David W Wetter; Charles E Green; Paul M Cinciripini
Journal:  Front Psychiatry       Date:  2013-09-23       Impact factor: 4.157

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.